Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05813314 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants
A Phase 1 study, sponsored by BioMarin Pharmaceutical.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT05813314 is a Phase 1 study that was terminated before completion, run by BioMarin Pharmaceutical. The registered enrollment target is 36 participants.
The verdict
NCT05813314, a Phase 1 study, was terminated before completion, sponsored by BioMarin Pharmaceutical.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the bioequivalence of a single SC dose of BMN 111 administered using a vial and syringe versus using an injector pen.
Interventions
- COMBINATION_PRODUCT BMN 111 administration via Injector Pen
- DRUG BMN 111 administration via vial and syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2023-06-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05813314
The ClinicalTrials.gov registry entry for NCT05813314 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMN 111 administration via Injector Pen is the first listed.
NCT05813314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05813314 about?
NCT05813314 is a clinical study titled "Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants". The purpose of this study is to establish the bioequivalence of a single SC dose of BMN 111 administered using a vial and syringe versus using an injector pen.
What is the current status of trial NCT05813314?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-03-15. Estimated completion is 2023-06-14.
What interventions are being tested in trial NCT05813314?
The interventions under investigation include: BMN 111 administration via Injector Pen (COMBINATION_PRODUCT), BMN 111 administration via vial and syringe (DRUG).
Who is sponsoring clinical trial NCT05813314?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.